| Oct 9 |
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
|
| Oct 8 |
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
|
| Oct 7 |
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year
|
| Oct 3 |
UBS sees more downside and than upside in Biogen stock
|
| Oct 2 |
Investors in Biogen (NASDAQ:BIIB) have unfortunately lost 32% over the last three years
|
| Oct 2 |
Biogen scrapped stroke drug helps patients walk independently in Phase III trial
|
| Oct 2 |
Biogen Inc. (BIIB): Among the Best Bargain Stocks to Buy In October
|
| Sep 27 |
SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324
|
| Sep 26 |
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
|
| Sep 26 |
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
|
